Eli Lilly, Incyte Get CHMP Backing for Olumiant in Adolescents With Severe Alopecia Areata
By Colin Kellaher
Eli Lilly and Incyte said a key European regulatory committee has recommended expanded approval of their Olumiant drug for adolescents with severe alopecia areata.
The companies on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the use of Olumiant in patients 12 and older with the autoimmune disease that causes sudden hair loss.
The European Commission, which generally follows the CHMP's advice, is expected to make a final decision in one to two months, the companies said.
Olumiant is already approved in Europe for people 18 and older with severe alopecia areata.
Indianapolis-based Eli Lilly in 2009 signed an agreement with Incyte, a Wilmington, Del., biopharmaceutical company, to develop and commercialize Olumiant for inflammatory and autoimmune diseases.
In addition to severe alopecia areata, Olumiant is approved in dozens of countries around the world for use in rheumatoid arthritis and atopic dermatitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2026 09:38 ET (14:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States